Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Biotechnology

Healthcare
$3.77 -3.37%

-$0.34 today

Market cap
$186.36M
Beta
2.40
P/E (TTM)
-2.7
EPS (TTM)
-$3.53
52W Low $1.47High $14.53

Volume 0.97M

Average 0.48M

ARTV Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Artiva Biotherapeutics, Inc.NASDAQ: ARTV

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$354.07M, compared with -$267M a year earlier.

Context

  • Retained earnings amounted to 334.2% of total assets at the end of Q1 FY2026, up 194.6 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -32.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$354.07M-7.1% QoQ
Last fiscal yearDec 2025
-$330.55M-34.0% YoY
Year agoMar 2025
-$267M-32.6% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-32.6%——
1 year-34.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(330.55M) USD
Year-over-year change
-34.0%

Retained Earnings vs competitors

How ARTV compares with its peers on the latest reported figures

  • Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -32.6% is the lowest of 9, against a peer median of -13.2%.
  • Retained earnings amounts to 334.2% of total assets for ARTV, versus a peer median of 460.4%.
ARTV Competitors
Retained Earnings for ARTV and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ARTVArtiva Biotherapeutics, Inc.Mar 2026-$354.07M USD-32.6%—334.2%
IFRXInflaRx N.V.Mar 2026-€383.82M EUR-12.7%—784.3%
CNTBConnect Biopharma Holdings LimitedDec 2025-$400.84M USD-16.1%—714.8%
STTKShattuck Labs, Inc.Mar 2026-$445.3M USD-12.6%—436.0%
DTILPrecision BioSciences, Inc.Mar 2026-$546.63M USD-8.7%—379.9%
GUTSFractyl Health, Inc. Common StockMar 2026-$547.05M USD-24.6%—550.4%
ALXOALX Oncology Holdings Inc.Mar 2026-$740.74M USD-13.6%—415.4%
STROSutro Biopharma, Inc.Mar 2026-$1.02B USD-17.8%—420.0%
ZNTLZentalis Pharmaceuticals, Inc.Mar 2026-$1.23B USD-11.3%—484.8%
Peer median (excluding ARTV) —-13.2%—460.4%

Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents160.92M102.53M53.5M40.24M26.7M
Short-term Investments0023.47M145.19M81.31M
Net Receivables468K525K1.76M146K767K
Inventory00000
Other Current Assets01.62M1.09M3.06M3.89M
Total Current Assets162.29M104.68M79.82M188.63M112.67M
Property, Plant & Equipment (Net)4.08M27.62M24.64M20.43M17.36M
Goodwill00000
Intangible Assets00000
Long-term Investments0245K000
Tax Assets00000
Other Non-current Assets3.56M517K650K525K919K
Total Non-current Assets7.64M28.38M25.29M20.95M18.27M
Total Assets169.93M133.05M105.11M209.58M130.94M
Account Payables1.44M1.1M614K1.12M355K
Short-term Debt00003.06M
Tax Payables00000
Deferred Revenue7.3M10.89M000
Other Current Liabilities00002.1M
Total Current Liabilities19.31M25.63M12.23M12.25M13.09M
Long-term Debt00007.88M
Deferred Tax Liabilities216.41M216.41M000
Deferred Revenue (Non-current)21.68M15.64M000
Other Non-current Liabilities81K115K241.59M73K0
Total Non-current Liabilities239.48M248.13M254.9M10.69M7.88M
Total Liabilities258.78M273.75M267.13M22.94M20.97M
Common Stock0003K3K
Retained Earnings(93.8M)(152.59M)(181.31M)(246.68M)(330.55M)
Accumulated OCI00308K(129K)103K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(88.86M)(140.7M)(162.02M)186.64M109.97M
Total Debt1.74M19.45M16.91M14.35M10.94M
Net Debt(159.18M)(83.08M)(36.59M)(25.88M)(15.76M)

Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Intrinsic Alpha fair value

Locked

Current Price

$3.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.